Research programme: anti-infectives - Oscient/sanofi-aventis
Latest Information Update: 24 Oct 2021
At a glance
- Originator sanofi-aventis
- Developer Oscient Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Mycoses
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
- 12 Feb 2004 Genome Therapeutics has merged with GeneSoft Pharmaceuticals